Emai£ºmarketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
Tel: +1(781)535-1428(U.S. - West Coast)
0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
µØµã£ºÉϺ£ÊÐÆÖ¶«ÐÂÇø´¨ºàáé585ºÅ
Óʱࣺ201299
µç»°£º+86 (21) 5859-1500£¨×Ü»ú£©
´«Õ棺+86 (21) 5859-6369
×èÖ¹±±¾©Ê±¼ä Êý¾ÝȪԴµÚÈý·½£¬½ö¹©²Î¿¼
ÏÖʵÐÅÏ¢Çë²Î¿¼£º¶«·½²Æ²úÍø
? 2023 williamÍþÁ®ÑÇÖÞ¹Ù·½ ±£´æËùÓÐȨÁ¦ »¦ICP±¸10216606ºÅ-3
»¦¹«Íø°²±¸ 31011502018888ºÅ | ÍøÕ¾µØͼ
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞ·þÎñ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 12ÔÂ6ÈÕ£¬CDE ¹ÙÍøÏÔʾ£¬ºãÈð1ÀàÐÂÒ© HRS-4729 ×¢ÉäÒºº£ÄÚÊ״λñÅúÁÙ´²£¬ÄâÓÃÓÚ³¬ÖØ»ò·ÊÅÖ¡£HRS-4729 ÊǺãÈð×ÔÖ÷Ñз¢µÄÏÂÒ»´ú³¦´ÙÒȵºËزúÆ·£¬Æ¾Ö¤ÏàÖúÆóÒµ¹ÙÍø¹ÜÏßÏÔʾ£¬ÕâÊÇÒ»¿î GLP1R/GIPR/GCGR Èý°Ðµã¼¤¶¯¼Á¡£
2. 12ÔÂ6ÈÕ£¬ÈðÆÕ³¿´´Ðû²¼CDEÅú×¼Á˺£ÄÚÊ׸ö¶àÐÑĿϸ°ûÌÇÄò²¡Ò©Æ·µÄÁÙ´²ÊÔÑé £¬ÓÃÓÚÖÎÁÆ1ÐÍÌÇÄò²¡¡£RGB-5088ÒȵºÏ¸°û×¢ÉäÒº¡£
3. 12ÔÂ5ÈÕ£¬CDE¹ÙÍø¹«Ê¾£¬ÓÉ°¢Ë¹Àû¿µ£¨AstraZeneca£©É걨µÄAZD2936ºÍDS-8201aÁ½¿îÐÂҩͬʱ»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬Ë³Ó¦Ö¢Îª¾Ö²¿ÍíÆÚ»òתÒÆÐÔHER2±í´ïµ¨µÀ°©»¼ÕßµÄÒ»ÏßÖÎÁÆ¡£
4. 12ÔÂ5ÈÕ£¬ÔÿµÒ©ÒµÐû²¼Í¨¸æ£¬ÆäÈ«×Ê×Ó¹«Ë¾º¼ÖÝÌìÁúÒ©ÒµÓÚ¿ËÈÕ»ñµÃÃÀ¹úFDA¹ØÓÚÔÞ³ÉYKYY026×¢ÉäÒºÓÃÓÚÔ¤·À´ø×´ðåÕî¾ÙÐÐÁÙ´²ÊÔÑéµÄº¯¸æ¡£YKYY026ÊÇÔÿµÒ©Òµ×ÔÖ÷¿ª·¢µÄÒ»¿î±àÂëË®¶»-´ø×´ðåÕ¶¾ (VZV)gEÂѰ׿¹ÔµÄmRNAÒßÃ磬ÓÃÓÚÔ¤·À´ø×´ðåÕî¡£
1. ¿ËÈÕ£¬GSKÐû²¼ÓëÖØÇìÖÇ·ÉÉúÎïÖÆÆ·¹É·ÝÓÐÏÞ¹«Ë¾¸æ¿¢ÐÂÐÒ飬½«Ë«·½µÄÕ½ÂÔÒßÃçÏàÖúÀ©Õ¹ÖÁ2034Äê¡£´Ë´ÎÏàÖúÉý¼¶£¬²»µ«ÑÓÉìÁËGSK´ø×´ðåÕîÒßÃç¡°ÐÀ°²Á¢ÊÊ¡±£¨Shingrix£©µÄÍƹãÏÞÆÚ£¬»¹½«Ì½Ë÷ºôÎüµÀºÏ°û²¡¶¾£¨RSV£©ÒßÃç Arexvy ÔÚÖйúÊг¡µÄÉÌÒµ»¯Ç±Á¦¡£Æ¾Ö¤ÐÒ飬Ԥ¼Æ2024ÄêÖÁ2029Äêʱ´ú£¬ÖÇ·ÉÉúÎï²É¹º¡°ÐÀ°²Á¢ÊÊ¡±µÄ×ܼÛÖµ¿ÉÄܸߴï23ÒÚÓ¢°÷£¬ÕÃÏÔÁËÏàÖúµÄÖ÷ÒªÐԺ͹æÄ£¡£
1. 12ÔÂ3ÈÕ£¬¹ú¼ÒÄÉÃ׿ÆѧÖÐÐÄÄô¹ã¾üÑо¿Ô±¡¢ÀîÒ»Ò¶Ñо¿Ô±µÈÔÚ Nature ×Ó¿¯ Nature Communications ÉϽÒÏþÁËÌâΪ£ºDual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine µÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿Éè¼ÆÁËÒ»ÖÖ³ÌÐò»¯ÄÉÃ×ϵͳ£¬ÒÔË«ÖؾÀÕý¹ý±í´ïÆÏÌÑÌÇתÔËÂÑ°×1£¨GLUT1£©ºÍCD71µÄÒÈÏÙµ¼¹ÜÏÙ°©£¨PDAC£©Ï¸°ûºÍÒÈÏÙÐÇ״ϸ°û£¨PSC£©µÄ´úлÒì³££¬ÓÃÓÚÖ×ÁöÖÎÁÆ¡£
[1]Wu, B., Wang, Z., Liu, J. et al. Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine. Nat Commun 15, 10526 (2024). https://doi.org/10.1038/s41467-024-54963-y